Neurological DiseasesANéRAVIMMNCT04846764
Rapid Declarative Neocortical Declarative Learning in Aging and Memory Diseases (ANéRAVIMM)
A study testing Neuropsychological tests in people with Neurological Diseases and Central Nervous System, run by Rennes University Hospital at 1 site in France.
Trial summary
Learning a person's name, new words, or simply remembering where the last conversation with a friend was held are examples of associative memory, frequently disturbed in brain pathologies, but also by aging. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Neurological Diseases, Central Nervous System
- What is being tested?
- Neuropsychological tests
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 97 participants
- Where
- 1 siteFrance
- Study dates
- 28 Apr 2021to 24 Mar 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Healthy Volunteers
- aged 18 to 40 years old and aged 60 to 80 years old
- native French speaker
- right-handed
- with a level of education greater than or equal to the Certificate of Primary Education
- free of any medical or psychiatric condition that may interfere with cognition
Show all 12Show fewer
- Neurological patients
- patients with mild neurocognitive impairment due to Alzheimer's disease
- patients with semantic dementia syndrome
- right-handed patients with a right or left unilateral surgical lesion of the anterior temporal lobe as a result of pharmaco resistant temporal epilepsy, with no seizures in the last 6 months, with a memory quotient greater than 75, and free of internal extra temporal lesions on MRI
- patients with autoimmune limbic encephalitis who have been seizure-free for one month
- 1 KA patient, suffering from the rare syndrome of developmental amnesia
Who cannot join
- All participants
- MRI contraindications
- sensory deficit interfering with experimental tests
- protected major (safeguard justice, trusteeship and guardianship) and persons deprived of liberty
- Healthy volunteers
- deficit score on the MoCA scale according to current calibrations
Show all 10Show fewer
- Neurologic patients
- 7-items modified Hachinski ischemic score >2
- dementia
- epileptic seizure in the month prior to inclusion for epileptic patients undergoing surgery and limbic encephalitis patients
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Rapid Declarative Neocortical Declarative Learning in Aging and Memory
Learning a person's name, new words, or simply remembering where the last conversation with a friend was held are examples of associative memory, frequently disturbed in brain pathologies, but also by aging. Although typically dependent on the hippocampus in the brain, a series of findings suggest that associative memory may persist, under certain circumstances, despite hippocampal damage. The ANéRAVIMM project aims to reveal this learning system, its cognitive and cerebral bases, and to evaluate its potential in patients with memory disorders.
Read the detailed description
Three experimental cognitive tasks will be used in the ANéRAVIMM study. The first two tasks have been selected based on the literature and previous work of CHU Rennes team. They are two experiments that have produced promising results concerning the existence of a rapid neocortical learning system in declarative memory, and have in common the use of prior knowledge to promote learning.
In the first part of the study, these two tasks will be put in competition for their resistance to the effects of age. Brain aging is characterized by its deleterious impact on hippocampal functioning, and memory aging leads to an alteration of associative memory. Therefore, this first part will allow the learning paradigm that presents the best potential in brain-damaged patients to be retained in the second part of the ANéRAVIMM study.
The third task stems from recent work by CHU Rennes team in collaboration with Dr. Besson of the University of Liege, in the context of a very recent model of memory. It aims at estimating the ability to develop a representation of visual objects in memory at the entity level, i.e. an integrated representation, unifying all the perceptual, conceptual and contextual features of perceived information. This task has been adapted for the ANéRAVIMM project in order to test the hypothesis that this mnemonic representational level of the entity in memory could support rapid neocortical associative learning in declarative memory.
- Conditions
- Neurological Diseases, Central Nervous System
- Being tested
- Neuropsychological tests
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Neuropsychological testsOther
Scales and tests to evaluate:
- laterality
- anxiety
- depression
- professional level
- education level
- pre-morbid level
- memory disorders
Experimental procedure
| Study group | Role | What they receive |
|---|---|---|
| Healthy volunteers | Active comparator | 60 healthy volunteers (aged 18-40 and 60-80) will undergo an inclusion visit in order to check inclusion and non inclusion criteria.
Then will be performed:
Visit 1
* Neuropsychological tests
* A cranial MRI
Visit 2
• Neuropsychological tests Receives: Other: Neuropsychological tests |
| Patients with neurological diseases of the central nervous system | Experimental | 36 patients will undergo an inclusion visit in order to check inclusion and non inclusion criteria.
Then will be performed:
Visit 1
* Neuropsychological tests
* A cranial MRI
Visit 2
• Neuropsychological tests Receives: Other: Neuropsychological tests |
What is being measured
The primary outcome is the main question the study is designed to answer.
Difference between young and old healthy subjects in experimental associative memory scores
Measured: Up to 1 month (time to perform the second visit)
Difference between healthy subjects and patients with SSHA damage in experimental associative memory scores
Measured: Up to 1 month (time to perform the second visit)
Correlations between SSHA volumes and experimental associative memory scores in healthy subjects and patients with SSHA damage
Measured: Up to 1 month (time to perform the second visit)
Correlations between rest-related functional connectivity within the Medial Temporal Lobes and experimental associative memory scores in healthy subjects
Measured: Up to 1 month (time to perform the second visit)
Secondary outcomes (1)
Presence of significant correlations between memory scores for entity-level mnemonic representations and experimental associative memory scores in healthy subjects
Measured: Up to 1 month (time to perform the second visit)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Apr 2021
- Study start28 Apr 2021
- Primary completion24 Mar 2025
- Study completion24 Mar 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Neurological DiseasesStudies of the same condition, open and under way.
- More trials run by Rennes University HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 97 participants (actual)
Sponsor and investigators
- Lead sponsor
- Rennes University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04846764
- Sponsor's protocol ID
- 35RC20_9796_ANéRAVIMM
- Acronym
- ANéRAVIMM
- Status last verified
- Jun 2026
- First submitted
- 22 Dec 2020
- Last updated
- 17 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 17 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Rapid Declarative Neocortical Declarative Learning in Aging and Memory
- ClinicalTrials.gov ID
- NCT04846764
- Acronym / sponsor ID
- ANéRAVIMM / 35RC20_9796_ANéRAVIMM
- Conditions
- Neurological Diseases, Central Nervous System
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 97 participants (actual)
- Lead sponsor
- Rennes University HospitalUniversity, hospital or other
- Study start
- 28 Apr 2021 (actual)
- Primary completion
- 24 Mar 2025 (actual)
- Study completion
- 24 Mar 2025 (actual)
- First posted
- 15 Apr 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Learning a person's name, new words, or simply remembering where the last conversation with a friend was held are examples of associative memory, frequently disturbed in brain pathologies, but also by aging. Although typically dependent on the hippocampus in the brain, a series of findings suggest that associative memory may persist, under certain circumstances, despite hippocampal damage. The ANéRAVIMM project aims to reveal this learning system, its cognitive and cerebral bases, and to evaluate its potential in patients with memory disorders.
Detailed description
Three experimental cognitive tasks will be used in the ANéRAVIMM study. The first two tasks have been selected based on the literature and previous work of CHU Rennes team. They are two experiments that have produced promising results concerning the existence of a rapid neocortical learning system in declarative memory, and have in common the use of prior knowledge to promote learning.
In the first part of the study, these two tasks will be put in competition for their resistance to the effects of age. Brain aging is characterized by its deleterious impact on hippocampal functioning, and memory aging leads to an alteration of associative memory. Therefore, this first part will allow the learning paradigm that presents the best potential in brain-damaged patients to be retained in the second part of the ANéRAVIMM study.
The third task stems from recent work by CHU Rennes team in collaboration with Dr. Besson of the University of Liege, in the context of a very recent model of memory. It aims at estimating the ability to develop a representation of visual objects in memory at the entity level, i.e. an integrated representation, unifying all the perceptual, conceptual and contextual features of perceived information. This task has been adapted for the ANéRAVIMM project in order to test the hypothesis that this mnemonic representational level of the entity in memory could support rapid neocortical associative learning in declarative memory.
Study design
- Primary purpose
- Other
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Healthy volunteers | Active comparator | Other: Neuropsychological tests60 healthy volunteers (aged 18-40 and 60-80) will undergo an inclusion visit in order to check inclusion and non inclusion criteria. Then will be performed: Visit 1 * Neuropsychological tests * A cranial MRI Visit 2 • Neuropsychological tests |
| Patients with neurological diseases of the central nervous system | Experimental | Other: Neuropsychological tests36 patients will undergo an inclusion visit in order to check inclusion and non inclusion criteria. Then will be performed: Visit 1 * Neuropsychological tests * A cranial MRI Visit 2 • Neuropsychological tests |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (12 listed)
- Healthy Volunteers
- aged 18 to 40 years old and aged 60 to 80 years old
- native French speaker
- right-handed
- with a level of education greater than or equal to the Certificate of Primary Education
Key exclusion criteria (10 listed)
- All participants
- MRI contraindications
- sensory deficit interfering with experimental tests
- protected major (safeguard justice, trusteeship and guardianship) and persons deprived of liberty
- Healthy volunteers
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Neuropsychological testsScales and tests to evaluate: * laterality * anxiety * depression * professional level * education level * pre-morbid level * memory disorders Experimental procedure | Other | Healthy volunteers, Patients with neurological diseases of the central nervous system |
Primary outcome
Difference between young and old healthy subjects in experimental associative memory scores
Time frame: Up to 1 month (time to perform the second visit)
Difference between healthy subjects and patients with SSHA damage in experimental associative memory scores
Time frame: Up to 1 month (time to perform the second visit)
Correlations between SSHA volumes and experimental associative memory scores in healthy subjects and patients with SSHA damage
Time frame: Up to 1 month (time to perform the second visit)
Correlations between rest-related functional connectivity within the Medial Temporal Lobes and experimental associative memory scores in healthy subjects
Time frame: Up to 1 month (time to perform the second visit)
1 secondary outcome
Presence of significant correlations between memory scores for entity-level mnemonic representations and experimental associative memory scores in healthy subjects
Time frame: Up to 1 month (time to perform the second visit)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Jun 2026.
Related trials for Neurological Diseases
Enrolling by invitation
Exercise Intervention for Breast Cancer Patients With Sarcopenia
Sarcopenia, Breast Cancer
RecruitingObservational study
Lemborexant vs Clonidine vs Sedatives to Treat Insomnia in Chronic Pain Patients
Chronic Insomnia, Chronic Pain
Active, not recruiting
The PorchLight Project
Memory Loss, Alzheimer Disease
Not yet recruitingPhase 4
Dexmedetomidine Versus Dexamethasone as Adjuvants to Bupivacaine in Ultrasound-Guided Sphenopalatine Ganglion Block for Functional Endoscopic Sinus Surgery
Post Operative Pain, Emergence Agitation
Active, not recruiting
Group Exercise Program Supported By Audiovisual Media During Hemodialysis
Chronic Kidney Failure, Hemodialysis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Neuropsychological tests in people with Neurological Diseases and Central Nervous System, run by Rennes University Hospital at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 12 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 17 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Difference between young and old healthy subjects in experimental associative memory scores (time frame: Up to 1 month (time to perform the second visit)). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Jun 2026.